Fresenius Medical Care, the world’s largest provider of products and services for individuals undergoing dialysis because of chronic kidney failure, anticipates a substantial increase in revenue and earnings for 2011. At the annual general meeting in Frankfurt/Main, Germany, today, Dr. Ben Lipps, the company’s Chief Executive Officer, confirmed Fresenius Medical Care’s full-year outlook, which was raised this month. The company expects revenues of over US$13 billion and net income between US$1.07 billion and US$1.09 billion in 2011.

“Fresenius Medical Care is well positioned for future growth in the dialysis market,” Lipps told shareholders. “We will continue to shape the future of the market and retain our leadership position. Making quality the priority, we will grow internationally, expand our product and service offerings and continue to innovate. Fresenius Medical Care will remain the world’s leading renal therapy company.”

Shareholders approved the 14th consecutive dividend increase with a large majority of 99.98%. The dividend will increase to €0.65 from €0.61 per ordinary share and to €0.67 from €0.63 per preference share.

As a result of the shareholder vote, the company’s supervisory board shall continue to include Dr. Gerd Krick as Chairman as well as Professor Bernd Fahrholz, William P. Johnston, Dr. Dieter Schenk and Walter L. Weisman. Rolf A. Classon, Chairman of Hill-Rom Holdings Inc., was elected as a new member of the supervisory board. Shareholders also endorsed the management board’s proposal to amend the supervisory board’s remuneration system. In addition to the existing fixed remuneration, a variable, performance-related remuneration component based on the company's long-term performance will be introduced. This is in line with recommendations contained in the German Corporate Governance Code.

With a further majority of 98.86%, shareholders also approved cancellation of the previous conditional capital for servicing expired stock options and subscription rights for employees. The creation of new conditional capital to provide for the company’s 2011 stock option program was also approved. For a period of five years, stockholders endorsed Fresenius Medical Care’s repurchase of up to 10 percent of its registered share capital for use in the company’s interest.

Shareholders approved the actions taken and decisions made by the supervisory board and the management board with a majority of more than 99%.

At the annual general meeting, 78.84% of the subscribed capital was represented. Only ordinary-share holders were entitled to vote. 

***

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,769 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 216,942 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

For more information about Fresenius Medical Care, visit the company’s website at <link www.fmc-ag.com>www.fmc-ag.com</link>.&nbsp;

Legal Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

***